As of 2025-09-18, the EV/EBITDA ratio of Fate Therapeutics Inc (FATE) is -0.44. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FATE's latest enterprise value is 68.31 mil USD. FATE's TTM EBITDA according to its financial statements is -156.19 mil USD. Dividing these 2 quantities gives us the above FATE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.0x - 14.5x | 13.0x |
| Forward P/E multiples | 11.0x - 16.7x | 13.6x |
| Fair Price | (14.57) - (19.31) | (17.65) |
| Upside | -1633.3% - -2132.2% | -1958.3% |
| Date | EV/EBITDA |
| 2025-09-18 | -0.48 |
| 2025-09-17 | -0.44 |
| 2025-09-16 | -0.44 |
| 2025-09-15 | -0.44 |
| 2025-09-12 | -0.45 |
| 2025-09-11 | -0.49 |
| 2025-09-10 | -0.47 |
| 2025-09-09 | -0.46 |
| 2025-09-08 | -0.45 |
| 2025-09-05 | -0.48 |
| 2025-09-04 | -0.45 |
| 2025-09-03 | -0.47 |
| 2025-09-02 | -0.50 |
| 2025-08-29 | -0.50 |
| 2025-08-28 | -0.53 |
| 2025-08-27 | -0.56 |
| 2025-08-26 | -0.56 |
| 2025-08-25 | -0.54 |
| 2025-08-22 | -0.59 |
| 2025-08-21 | -0.56 |
| 2025-08-20 | -0.57 |
| 2025-08-19 | -0.58 |
| 2025-08-18 | -0.62 |
| 2025-08-15 | -0.54 |
| 2025-08-14 | -0.53 |
| 2025-08-13 | -0.57 |
| 2025-08-12 | -0.43 |
| 2025-08-11 | -0.43 |
| 2025-08-08 | -0.42 |
| 2025-08-07 | -0.46 |
| 2025-08-06 | -0.50 |
| 2025-08-05 | -0.53 |
| 2025-08-04 | -0.52 |
| 2025-08-01 | -0.53 |
| 2025-07-31 | -0.55 |
| 2025-07-30 | -0.58 |
| 2025-07-29 | -0.60 |
| 2025-07-28 | -0.70 |
| 2025-07-25 | -0.65 |
| 2025-07-24 | -0.66 |
| 2025-07-23 | -0.68 |
| 2025-07-22 | -0.65 |
| 2025-07-21 | -0.59 |
| 2025-07-18 | -0.57 |
| 2025-07-17 | -0.59 |
| 2025-07-16 | -0.57 |
| 2025-07-15 | -0.57 |
| 2025-07-14 | -0.58 |
| 2025-07-11 | -0.59 |
| 2025-07-10 | -0.59 |